Advert - Bayer Schering Pharma

For being involved in the generation and distribution of a prescribing policy document on vardenafil (Levitra) that was described as being 'Supported by an educational grant', bayer Schering Pharma was ruled in breach of the following clause of the Code:

Clause 4.1 - Failing to include prescribing information.

The Code of Practice Panel reported the company to the Code of Practice Appeal Board. During its consideration of the matter, the Appeal Board learnt that the material was circulated more widely than previously indicated.

For failing to provide comprehensive information to the Authority, Bayer was publicly reprimanded by the Appeal Board.